<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="ppub"/></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS159172</article-id><article-id pub-id-type="doi">10.1101/2022.12.28.522082</article-id><article-id pub-id-type="archive">PPR590125</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group><subj-group subj-group-type="europepmc-category"><subject>Covid-19</subject></subj-group></article-categories><title-group><article-title>Erythromycin, Retapamulin, Pyridoxine, Folic acid and Ivermectin dose dependently inhibit cytopathic effect, Papain-like Protease and M<sup>PRO</sup> of SARS-CoV-2</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bello</surname><given-names>Shaibu Oricha</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib><contrib contrib-type="author"><name><surname>Imam</surname><given-names>Mustapha Umar</given-names></name><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Bello</surname><given-names>Muhammad Bashir</given-names></name><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Yunusa</surname><given-names>Abdulmajeed</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Adamu</surname><given-names>Adamu Ahmed</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Shuaibu</surname><given-names>Abdulmalik</given-names></name><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Igumbor</surname><given-names>Ehimario Uche</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Habib</surname><given-names>Zaiyad Garba</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Popoola</surname><given-names>Mustapha Ayodele</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ochu</surname><given-names>Chinwe Lucia</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Bello</surname><given-names>Aishatu Yahaya</given-names></name><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Deeni</surname><given-names>Yusuf Yahaya</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A10">10</xref><xref ref-type="aff" rid="A11">11</xref></contrib><contrib contrib-type="author"><name><surname>Okoye</surname><given-names>Ifeoma</given-names></name><xref ref-type="aff" rid="A12">12</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Pharmacology and Therapeutics, Faculty of Basic Clinical Sciences, College of Health Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria</aff><aff id="A2"><label>2</label>Nigerian COVID-19 Research Coalition, Nigerian Institute of Medical Research Institute, Abuja</aff><aff id="A3"><label>3</label>Centre for Advanced Medical Research and Training, Usmanu Danfodiyo University, Sokoto, Nigeria</aff><aff id="A4"><label>4</label>Department of Medical Biochemistry, Usmanu Danfodiyo University, Sokoto, Nigeria</aff><aff id="A5"><label>5</label>Department of veterinary Microbiology, Usmanu Danfodiyo University, Sokoto, Nigeria</aff><aff id="A6"><label>6</label>School of Public Health, University of the Western Cape, Cape Town, South Africa</aff><aff id="A7"><label>7</label>Department of Medicine, University of Abuja Teaching Hospital, Gwagwalada, Abuja</aff><aff id="A8"><label>8</label>Nigerian Centre for Disease Control and Prevention, Abuja, Nigeria</aff><aff id="A9"><label>9</label>Department of Clinical pharmacy and Pharmacy Practice, Faculty of Pharmaceutical sciences, Usmanu Danfodiyo University, Sokoto, Nigeria</aff><aff id="A10"><label>10</label>Department of Microbiology and Biotechnology, Federal University of Dutse, Dutse, Nigeria</aff><aff id="A11"><label>11</label>Centre for Environmental and Public Health Research and Development, Kano, Nigeria</aff><aff id="A12"><label>12</label>University of Nigeria Centre for Clinical Trials, University of Nigeria Teaching Hospital, Enugu, Ituku Ozalla, Nigeria</aff><author-notes><corresp id="CR1">
<label>*</label>Correspondence: Shaibu Oricha Bello, Department of Pharmacology and Therapeutics, Faculty of Basic Clinical Sciences, College of Health Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria. <email>oricha.bello@udusok.edu.ng</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>01</day><month>01</month><year>2023</year></pub-date><pub-date pub-type="preprint"><day>29</day><month>12</month><year>2022</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p></license><license><ali:license_ref>https://europepmc.org/downloads/openaccess</ali:license_ref><license-p>This preprint is made available via the <ext-link ext-link-type="uri" xlink:href="https://europepmc.org/downloads/openaccess">Europe PMC open access subset</ext-link>, for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original preprint source.</license-p></license></permissions><abstract><p id="P1">We previously showed that Erythromycin, Retapamulin, Pyridoxine, Folic acid and Ivermectin inhibit SARS-COV-2 induced cytopathic effect (CPE) in Vero cells. In this study and using validated quantitative neutral red assay, we show that the inhibition of CPE is concentration dependent with Inhibitory Concentration-50(IC<sub>50</sub>) of 3.27 μM, 4.23 μM, 9.29 μM, 3.19 μM and 84.31 μM respectively. Furthermore, Erythromycin, Retapamulin, Pyridoxine, Folic acid and Ivermectin dose dependently inhibit SARS-CoV-2 Papain-like Protease with IC<sub>50</sub> of 0.94 μM, 0.88 μM, 1.14 μM, 1.07 μM, 1.51 μM respectively and the main protease(M<sup>PRO</sup>) with IC<sub>50</sub> of 1.35 μM, 1.25 μM, 7.36 μM, 1.15 μM and 2.44 μM respectively. The IC<sub>50</sub> for all the drugs, except ivermectin, are at the clinically achievable plasma concentration in human, which supports a possible role for the drugs in the management of COVID-19. The lack of inhibition of CPE by Ivermectin at clinical concentrations could be part of the explanation for its lack of effectiveness in clinical trials.</p></abstract></article-meta></front><body><sec id="S1" sec-type="intro"><label>1</label><title>Introduction</title><p id="P2">A major lesson learned from the Spanish flu of 1918 is that pandemics can rapidly decimate a population<sup><xref ref-type="bibr" rid="R1">1</xref></sup>. In the current COVID-19 pandemic, which started in Wuhan China in December 2019, as of 13/11/2022, over 635million cases have been reported worldwide with over 6.61 Million deaths<sup><xref ref-type="bibr" rid="R2">2</xref></sup>. While the world continues to take measures aimed at keeping the incidence low and limiting the spread, it is important to identify therapeutics that may mitigate COVID-19 in those who do get infected and develop the disease. Although the world has risen to the challenge and there are over 400 drug candidates, most are based on new therapies that, if found effective, are not expected to be available in developing economies within 2 years due to market prioritization usually mostly imposed by limited production capacities of new drugs. Meanwhile, few candidate therapies have consistently been effective in ameliorating the duration of infection or the severity of the illness. Other than Dexamethasone and related steroid, Lopinavir-Ritonavir (Paxlovid) and Remdesivir are not available in most countries and are, nevertheless, effectively out of reach to most people due to cost. A huge therapeutic gap in COVID-19, therefore, remains.</p><p id="P3">COVID-19 is predominantly asymptomatic (80% of cases) <sup><xref ref-type="bibr" rid="R3">3</xref></sup>. When symptomatic, the clinical presentation is that of respiratory infection with severity ranging from a mild common cold-like illness to severe viral pneumonia leading to acute respiratory distress syndrome that is potentially fatal <sup><xref ref-type="bibr" rid="R3">3</xref></sup>. Knowledge of the pathogenesis of COVID-19 is still evolving but the structure of the virus, mechanisms of viral entry, and replications are essentially settled and appears target rich for drug discovery and development. It is, therefore, difficult to explain why many candidate therapies perform excellently well in-vitro but fail in clinical trials. The reason may include the presence of unresolved redundant pathways or a dis-linkage between viremia and pathology. Whichever, it is becoming clear that therapies that target multiple pathways in the pathogenesis of COVID-19 may prove superior.</p><p id="P4">Our team previously developed and validated an algorithm that involves deliberate consideration of multiple targets, cost, toxicity, and availability in selecting drugs for rapid repurposing efforts with off-label application as the immediate goal<sup><xref ref-type="bibr" rid="R4">4</xref></sup>. SARS-CoV-2 induced cytopathic effect(CPE) has previously been validated as a surrogate for SARS-CoV-2 infectivity and de-isolation which is non-inferior to PCR<sup><xref ref-type="bibr" rid="R5">5</xref></sup>. Therefore, in our previous study<sup><xref ref-type="bibr" rid="R4">4</xref></sup> demonstration of inhibition of CPE was considered more cost-effective and a surrogate of clinical efficacy than demonstration of inhibition of viral multiplication alone due to the possibility of threshold effect in viral induced CPE<sup><xref ref-type="bibr" rid="R6">6</xref></sup>. We also identified Erythromycin, Pyridoxine, Folic acid and Ivermectin as potential drugs to repurpose for COVID-19 ; with wet laboratory demonstration of inhibition(qualitative assay) of SARS-COV-2 induced CPE in Vero cells and in-silico prediction of inhibition of multiple critical SARS-CoV-2 enzymes<sup><xref ref-type="bibr" rid="R4">4</xref></sup>.</p><p id="P5">This study was conducted to further evaluate Erythromycin, Pyridoxine, Folic acid and Ivermectin as potential drugs for COVID-19 by measuring quantitative concentration dependent inhibition of CPE, SARS-CoV-2 Papain-like Protease and SARS-CoV-2 3CL Main Protease(M<sup>PRO</sup>).</p></sec><sec id="S2" sec-type="materials | methods"><label>2</label><title>Materials and Methods</title><sec id="S3" sec-type="materials"><label>2.1</label><title>Materials</title><p id="P6">SensoLyte® 520 SARS-CoV-2 M<sup>PRO</sup> Activity Assay Kit, SensoLyte® 520 SARS-CoV-2 Papain-like Protease/ Deubiq, Molecular grade water, Neutral red (3-amino-7-dimethylamino-2-methyl-phenazine hydrochloride) (Solarbio, cat. N8160), Minimal Essential Medium/Earls Balance Salts (MEM/EBSS) (HyClone laboratories, Utah, USA), Glacial acetic acid, Ethanol 96% 0.4% (wt./vol), Trypan blue in 0.9% NaCl solution, SARS-CoV-2, Virus (clinical isolate), and cell cultureware from Nest (Jiangsu, China) were used in this study.</p></sec><sec id="S4"><label>2.2</label><title>Cell culture procedure</title><p id="P7">Vero cell preparation, passaging, SARS-CoV-2 virus, and sources of experimental drugs were as previously described<sup><xref ref-type="bibr" rid="R4">4</xref></sup>. Three different doses of each drug were tested for antiviral activity: Erythromycin, Retapamulin, Folic acid and Ivermectin were tested at 5μM, 7.5μM and 10μM, while Pyridoxine was tested at 10 μM, 15 μM and 20 μM, all in three independent replicates. Briefly, we seeded 96-well plates with 6x10<sup>4</sup> cells/mL of Vero E6 (200 μL per well), using Minimum Essential Medium (MEM) with 10% fetal bovine serum (FBS) without antibiotics. Plates were incubated overnight at 37 °C in a 5% CO2 atmosphere. The following day, the 96 wells plates were viewed under an inverted microscope for a confluence of about 50%. Sixty minutes before drug treatment, cell culture supernatant was removed from each well and the wells were washed with 150 μL phosphate buffered saline (PBS). Except for the negative and cell growth control wells where 50 μL of PBS was added, each well was infected with 50 μL SARS-CoV-2 diluted in PBS at a multiplicity of infection (MOI) of 0.1 and incubated for 1 hour at 37 °C in 5% CO2 with intermittent shaking of the plates at 15 minutes interval to allow for viral adsorption. Thereafter, the infection supernatant was removed and 200 μL of the respective drugs diluted in MEM/EBSS having 1% FBS without antibiotics were added to the different treatment groups and incubated at 37 °C in 5% CO2. The cells were viewed using an inverted microscope after 48 hours to check for CPE.</p></sec><sec id="S5"><label>2.3</label><title>Quantification of Inhibition of SARS-COV-2 induced CPE using Neutral Red (NR) assay</title><p id="P8">Neutral red (NR) assay<sup><xref ref-type="bibr" rid="R7">7</xref></sup> was used to quantify cell viability and the inhibition of CPE. The NR uptake assay provides a quantitative estimation of the number of viable cells in culture. It is based on the ability of viable cells to incorporate and bind the neutral red dye in the lysosomes which are then extracted using glacial acid for measurement of optical densities using a spectrophotometer<sup><xref ref-type="bibr" rid="R8">8</xref></sup>.</p><p id="P9">Briefly, an overnight incubated 40 μg ml<sup>-1</sup> NR working solution (in MEM) was filtered using a 2 μm membrane filter to remove any precipitated dye crystals. The attached cells from the in vitro antiviral activity experiments were washed with 150 μL PBS per well and the washing solution was removed. The NR medium was gently placed in a reservoir and 100 μL of the NR medium was pipetted to each well of the plates. The plates were incubated for 2 h under the proper culture conditions. After the period of incubation, the plates were inspected with an inverted microscope to check the possible precipitation of NR. The medium was removed, and the cells were washed 2 times with 150 μL PBS per well. Thereafter 150 μL NR destain solution was added per well and the plates were shaken rapidly on a microtiter plate shaker at 500 rpm for 10 min.</p><p id="P10">The optical densities of extracted neutral red were measured at 540 nm in a microtiter plate reader. Blank was subtracted from the resulting absorbance values prior to data analysis. The groups were (i) Virus infected cells(virus control), (ii) Virus infected and treated cells(Treatment group) and (iii) Cells with no virus nor drug treatment(Growth control). Growth and inhibition of CPE was determined relative to the growth the untreated control.</p></sec><sec id="S6"><label>2.4</label><title>Inhibition of SARS-CoV-2 Papain-like protease activity</title><p id="P11">All working solutions were prepared according to manufacturer instructions. The enzymatic reaction was set up by adding 10 μL per well of three respective concentrations of Erythromycin, Retapamulin, Folic acid, Ivermectin (2.5μM, 5μM and 10μM) and pyridoxine (5 μM, 10 μM and 20 μM). Dose spacing was designed to be within the achievable plasma concentration of the drugs. Each test was done in triplicate.</p><p id="P12">Briefly, 40 μL diluted enzyme working solution was added to each microplate wells. Simultaneously the following control wells were set up. <list list-type="roman-lower" id="L1"><list-item><p id="P13">Positive control containing 40 μL of Papain-like protease without the test drugs.</p></list-item><list-item><p id="P14">Inhibitor control containing 40 μL Papain-like protease and 10 μL of GRL0617.</p></list-item><list-item><p id="P15">Two vehicle control containing 40 μL Papain-like protease and 10 μL vehicle used in delivering test compound (0.1% DMSO).</p></list-item><list-item><p id="P16">Test compound control containing assay buffer and 10 μL test compound.</p></list-item><list-item><p id="P17">Substrate control containing assay buffer.</p></list-item><list-item><p id="P18">Assay buffer was used to bring the total volume of all controls to 50 μL.</p></list-item></list></p><p id="P19">To each well, 50 μL of Papain-like protease, substrate solution was added, and the reagents were mixed by shaking the plate gently for 30 sec. the plates were then incubated away from direct light at 37°C for up to 60 min. The fluorescence intensity was measured at excitation and emission wavelength of 490 nm and 520 nm.</p></sec><sec id="S7"><label>2.5</label><title>Inhibition of SARS-CoV-2, M<sup>PRO</sup> activity</title><p id="P20">The experimental set up and the relevant controls were as with the Inhibition of SARS-CoV-2 Papain-like protease activity assay, except that the SARS-CoV-2 M<sup>PRO</sup> enzyme and activity assay kit was used according to manufacturer’s protocol.</p></sec></sec><sec id="S8"><label>3.0</label><title>Data Analysis</title><p id="P21">Statistical software GraphPad Prism 9.4.1, NCSS 2022 and Microsoft excel were used for data analysis and Graphical representations. We checked data for outliers using the Tukey’s box-plot method (interquartile principle)<sup><xref ref-type="bibr" rid="R9">9</xref></sup>. However, outliers were included in the analysis of CPE inhibition because biological reasons may be involved<sup><xref ref-type="bibr" rid="R9">9</xref></sup>. Furthermore, we substituted outliers by the group average in the enzyme assays because precision is more likely involved<sup><xref ref-type="bibr" rid="R10">10</xref></sup>. Nonetheless, sensitivity analysis was conducted by including outliers in the enzyme assays. Percentage Inhibition of CPE was calculated from the optical densities according to Severson <italic>et al</italic><sup><xref ref-type="bibr" rid="R11">11</xref></sup>: <inline-formula><mml:math id="M1"><mml:mrow><mml:mfrac><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>T</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mspace width="0.2em"/><mml:mi>s</mml:mi><mml:mi>u</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mo>−</mml:mo><mml:mi>V</mml:mi><mml:mi>i</mml:mi><mml:mi>r</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi><mml:mspace width="0.2em"/><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>C</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi><mml:mspace width="0.2em"/><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mo>−</mml:mo><mml:mi>V</mml:mi><mml:mi>i</mml:mi><mml:mi>r</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi><mml:mspace width="0.2em"/><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>∗</mml:mo><mml:mn>100</mml:mn><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> provided the concentrations of test drug was nontoxic to Vero cells in a separate assay. Although Severson <italic>et al</italic> considered inhibition of CPE ≥ 50% as hits in their study, we accepted inhibitions of CPE ≥ 15% as hits because this was not a full range dose-response study, but concentrations were restricted to those achievable within the human plasma at routine dosing schedules. Maximum responses (efficacy) were, therefore, conceivably different from what we observed. Percentage inhibition of enzyme activity was calculated according to manufacturer’s instruction and essentially represented as: <inline-formula><mml:math id="M2"><mml:mrow><mml:mfrac><mml:mrow><mml:mtext>RFU</mml:mtext><mml:mspace width="0.2em"/><mml:mtext>Negative</mml:mtext><mml:mspace width="0.2em"/><mml:mtext>control</mml:mtext><mml:mo>−</mml:mo><mml:mtext>RFU</mml:mtext><mml:mspace width="0.2em"/><mml:mtext>Test</mml:mtext></mml:mrow><mml:mrow><mml:mtext>RFU</mml:mtext><mml:mspace width="0.2em"/><mml:mtext>Negative</mml:mtext><mml:mspace width="0.2em"/><mml:mtext>control</mml:mtext></mml:mrow></mml:mfrac><mml:mo>∗</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:math></inline-formula> (after subtracting the blank), where RFU is the Relative Fluorescent Unit. The Concentration that gave 50% response(EC<sub>50</sub> or IC<sub>50</sub>) was determined by first visual inspection of the dose response plot to infer possible models<sup><xref ref-type="bibr" rid="R12">12</xref></sup>. Maximum and minimum responses were constrained to 100% and 0% respectively because these were the only possible outcomes in data normalized to percentage response. Nonlinear regression three parameters dose-response models were used on the primary runs but compared to alternate models with higher R-square used to decide the best model. Furthermore, 95% Confidence Interval (CI) was determined for all estimates. In determining the 95% CI, unknowns were interpolated from standard curve. In the CPE evaluation all comparisons were to SARS-CoV-2 infected but vehicle (DMSO) treated Vero Cells. In the enzyme inhibition assay, all comparisons were to the uninhibited enzyme activity. In both enzyme inhibition assays, manufacturer supplied inhibitor controls were used to ascertain the integrity of the system. Level of significance was set at <italic>p</italic>&lt;0.05.</p></sec><sec id="S9" sec-type="results"><label>4.0</label><title>Result</title><sec id="S10"><label>4.1</label><title>Inhibition of SARS-CoV-2 induced CPE</title><p id="P22">All tested doses of the drugs alone were not toxic to Vero cells.</p><p id="P23">Erythromycin, retapamulin, pyridoxine and folic acid dose dependently and significantly (p=0.0005) inhibited SARS-CoV-2 induced CPE with maximum inhibition of 76%, 75%, 63% and 42% respectively at the tested doses. However, the maximum inhibition of CPE by ivermectin was 10% (at 10 μM) and this was not significant (p=0.5)(<xref ref-type="table" rid="T1">Table 1</xref> and <xref ref-type="fig" rid="F1">Figure 1</xref>).</p></sec><sec id="S11"><label>4.2</label><title>Inhibition of SARS-CoV-2 Papain like Protease</title><p id="P24">Erythromycin, retapamulin, pyridoxine, folic acid and ivermectin dose dependently and significantly (p&lt;0.05) inhibited SARS-CoV-2 papain like protease with maximum inhibition of 29.46%, 20.60%, 17.46%, 31.99% and 34.34% respectively at the tested doses (<xref ref-type="table" rid="T2">Table 2</xref> and <xref ref-type="fig" rid="F2">Figure 2</xref>).</p></sec><sec id="S12"><label>4.3</label><title>Inhibition of SARS-CoV-2 Main Protease (M<sup>PRO</sup> or 3CL protease)</title><p id="P25">Erythromycin, retapamulin, pyridoxine, folic acid and ivermectin dose dependently and significantly (p&lt;0.05) inhibited SARS-CoV-2 M<sup>PRO</sup> with maximum inhibition of 30.51%, 33.37%, 45.1%, 26.8% and 38.07% respectively at the tested doses (<xref ref-type="table" rid="T3">Table 3</xref> and <xref ref-type="fig" rid="F3">Figure 3</xref>).</p></sec></sec><sec id="S13" sec-type="discussion"><label>5.0</label><title>Discussion</title><p id="P26">This study was conducted as standalone evaluation of the effect of drugs previously identified by in silico screening<sup><xref ref-type="bibr" rid="R4">4</xref></sup> as potential therapeutics for SARS-CoV-2 infection and COVID-19. Although effect on SARS-CoV-2 induced CPE in Vero cells, SARS-CoV-2 Main protease (M<sup>PRO</sup>) and Papain-like protease (PP) were evaluated, these were not considered necessarily linked (mechanistic) because the initial in silico selection was based on predicted activity at 11 independent targets<sup><xref ref-type="bibr" rid="R4">4</xref></sup>, any combination of which may be related to observed inhibition of CPE. It is interesting that Nirmatrelvir-ritonavir combination(Paxlovid)<sup><xref ref-type="bibr" rid="R17">17</xref>,<xref ref-type="bibr" rid="R18">18</xref></sup>, the current forerunner in COVID-19 therapeutics is an M<sup>PRO</sup> inhibitor and it is accepted that its efficacy is related to this inhibition<sup><xref ref-type="bibr" rid="R19">19</xref></sup>.</p><p id="P27">Erythromycin, retapamulin and pyridoxine significantly inhibited SARS-CoV-2 induced CPE in Vero cells to an extent that met our criteria (based on anticipated combination therapy) (≥15%) and that of Severson <italic>et al</italic> (based on anticipated monotherapy) (≥50%)<sup><xref ref-type="bibr" rid="R11">11</xref></sup> to define hits. It is reassuring that the CPE inhibitions were at concentrations and IC<sub>50</sub> that were consistent with achievable plasma levels at current recommended doses(Erythromycin and pyridoxine) or formulations (Retapamulin) of these drugs. Furthermore, erythromycin, retapamulin and pyridoxine significantly inhibited SARS-CoV-2 M<sup>PRO</sup> and PP at achievable concentrations and IC<sub>50</sub>. To the best of our knowledge, this is the first study identifying erythromycin and retapamulin as potential therapeutics for COVID-19. Pyridoxine has previously been reported as a useful supplementary therapy for COVID-19 but this was in context unrelated to its antiviral activity<sup><xref ref-type="bibr" rid="R20">20</xref>,<xref ref-type="bibr" rid="R21">21</xref></sup>.</p><p id="P28">Folic acid significantly inhibited SARS-CoV-2 induced CPE with maximum inhibition of 42% at clinically achievable concentration of 5 μM, thus satisfying our criteria for hits but falling short of the criteria of Severson <italic>et al</italic><sup><xref ref-type="bibr" rid="R11">11</xref></sup>. Furthermore, the dose response pattern suggest that lower doses are more effective than higher doses suggesting that higher doses may be toxic to Vero cells in the presence of SARS-CoV-2 viruses because, as reported above, the tested doses of the drug (alone) were not found to be toxic to Vero-cells in the cell toxicity study. This pattern of lower dose being more effective is also observed in Folic acid’s significant inhibition of SARS-CoV-2 M<sup>PRO</sup>. The immediate implication of these findings is uncertain beyond the desirable recommendation that lower doses of folic acid should be the target of future possible utilization of Folic acid in SARS-CoV-2 infections. This is contrary to the suggestion of Asad <italic>et al</italic><sup><xref ref-type="bibr" rid="R22">22</xref></sup> that higher dose of folic acid would be beneficial in COVID-19; though the suggestion was based on studies that examined the inhibition of Spike protein by folic acid<sup><xref ref-type="bibr" rid="R23">23</xref></sup>. Folic acid also significantly inhibits SARS-CoV-2 Papain like protease and at concentrations and IC<sub>50</sub> that are also achievable at routine therapeutic doses. Indeed, previous molecular docking studies by our group<sup><xref ref-type="bibr" rid="R4">4</xref></sup> and others<sup><xref ref-type="bibr" rid="R24">24</xref></sup> suggest Folic acid as potential therapeutic in COVID-19. Wet laboratory studies further suggest that Folic acid inhibits SARS-COV-2 nucleocapsid protein<sup><xref ref-type="bibr" rid="R25">25</xref></sup> and inhibits cell invasion by SARS-CoV-2 by methylating ACE2<sup><xref ref-type="bibr" rid="R26">26</xref></sup>. The relationship between a particular enzyme inhibition and inhibition of CPE is therefore not immediately certain. Perhaps, combination effect may be an explanation.</p><p id="P29">Ivermectin significantly inhibited SARS-CoV-2 M<sup>PRO</sup> and PP with either greater or equivalent percentage inhibition compared to other drugs tested. Nonetheless, ivermectin failed to significantly inhibit SARS-CoV-2 induced CPE. These findings may partly explain the lack of clinical efficacy of ivermectin in various clinical trials<sup><xref ref-type="bibr" rid="R27">27</xref>–<xref ref-type="bibr" rid="R29">29</xref></sup> despite the fact that at very high doses(1,200μg/Kg), started early in the disease <sup><xref ref-type="bibr" rid="R30">30</xref></sup>, ivermectin potently inhibit viral replication with up to 5000 fold reduction in viral load<sup><xref ref-type="bibr" rid="R13">13</xref></sup>. In any case, it is important to note that the concentrations of ivermectin under consideration are not achievable clinically at current recommended doses of &lt;200μg/Kg<sup><xref ref-type="bibr" rid="R14">14</xref>,<xref ref-type="bibr" rid="R15">15</xref>,<xref ref-type="bibr" rid="R31">31</xref></sup>. Nonetheless, our findings further point towards CPE and/or cell based assays as, perhaps, more clinically relevant endpoints in screening therapeutics against SARS-CoV-2<sup><xref ref-type="bibr" rid="R5">5</xref>,<xref ref-type="bibr" rid="R11">11</xref>,<xref ref-type="bibr" rid="R32">32</xref></sup>.</p><sec id="S14"><title>Limitations of the study</title><p id="P30">A limitation of this study is that a limited dose span and restricted dose escalations were used which did not allow for the exploration of the full range of effects of the drugs. However, the restrictions were important in the presence of usual budget constraints, and to focus on achievable concentrations in human plasma because off-label use rather than expanded label was the theoretical framework of this study. Such full-range dose studies will still need to be done if expanded drug labelling that may involve alternative delivery systems are under consideration. Another limitation is that the studies were conducted between three different collaborating laboratories that may have different laboratory fidelities. Nonetheless, this was a pre-identified challenge and steps were taken to harmonize workflow between laboratories and thus enhance data integrity. Even then, no experiment conducted in one laboratory was re-run in another collaborating laboratory. Also, although we estimated IC<sub>50</sub> in this study, the point estimates should be interpreted with caution because of the possibility of non-monotonicity in the response, a known drawback of IC<sub>50</sub>/EC<sub>50</sub> estimations<sup><xref ref-type="bibr" rid="R33">33</xref></sup>(for example, the CPE and M<sup>PRO</sup> inhibitions of retapamulin appears ‘n’ shaped and ‘u’ shaped respectively)(<xref ref-type="fig" rid="F1">Figures 1</xref> and <xref ref-type="fig" rid="F3">3</xref>). The 95% CI estimates of the IC<sub>50</sub> provide some reassurance, but again these were estimated by using the accepted method of inputting unknown data from standard curves<sup><xref ref-type="bibr" rid="R34">34</xref>,<xref ref-type="bibr" rid="R35">35</xref></sup>. Nonetheless, the strengths of the study are the use of validated cell-based assays, ease of running the experiments in moderately equipped laboratories (International Standard Organization Level 2<sup><xref ref-type="bibr" rid="R36">36</xref></sup>) and the detection of acceptable level of effects at therapeutic concentrations of the drugs.</p></sec></sec><sec id="S15" sec-type="conclusions"><title>Conclusion</title><p id="P31">In this study, we identified erythromycin, retapamulin, pyridoxine and folic acid as potential therapeutic agents for COVID-19 and provided evidence that ivermectin may not be effective. Because full or close to full effect (100% inhibition) is an ideal target of drug therapy and none of the drugs achieved this at therapeutic doses, combination therapy is recommended though synergism may not be guaranteed. Such combinations may be evaluated in a randomized control trial using the basket or umbrella design<sup><xref ref-type="bibr" rid="R37">37</xref></sup>. Such a trial will need careful design and funding consideration. Meanwhile, we consider that the evidence provided by this study is sufficient for consideration of off-label use of these drugs in COVID-19 situations ; given that the evidence is consistent and comparable with those available for drugs currently on clinical trials<sup><xref ref-type="bibr" rid="R38">38</xref>,<xref ref-type="bibr" rid="R39">39</xref></sup> and probably superior to those currently on off-label use<sup><xref ref-type="bibr" rid="R40">40</xref>,<xref ref-type="bibr" rid="R41">41</xref></sup>. We also recommend that all off-label prescriptions, while maintaining standard ethical requirements, should include robust and objective documentation of patients’ status and drug dosing to provide <italic>preliminary insight</italic> into the effectiveness of the drugs. Such <italic>Preliminary Insight documentation</italic> should be routine in off-label prescriptions but may not and cannot replace randomized trials. In this regard, risk of abuse of documented off-label prescription, like using it as convenient alternative to clinical trials, should be recognized and mitigated<sup><xref ref-type="bibr" rid="R41">41</xref></sup>.</p></sec></body><back><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shanks</surname><given-names>GD</given-names></name><name><surname>Wilson</surname><given-names>N</given-names></name><name><surname>Kippen</surname><given-names>R</given-names></name><name><surname>Brundage</surname><given-names>JF</given-names></name></person-group><article-title>The unusually diverse mortality patterns in the Pacific region during the 1918–21 influenza pandemic: reflections at the pandemic’s centenary</article-title><source>The Lancet Infectious Diseases</source><year>2018</year><volume>18</volume><fpage>e323</fpage><lpage>e332</lpage><pub-id pub-id-type="pmid">29754745</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Gates</surname><given-names>M</given-names></name></person-group><article-title>What are your thoughts on Our World In Data website ? [ D ] Open Lecture on Statistics and Data by a</article-title><year>2020</year><fpage>1</fpage><lpage>11</lpage></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Sousa</surname><given-names>E</given-names></name><etal/></person-group><article-title>Mortality in COVID-19 disease patients: Correlating the association of major histocompatibility complex (MHC) with severe acute respiratory syndrome 2 (SARS-CoV-2) variants</article-title><source>Int J Infect Dis</source><year>2020</year><volume>98</volume><fpage>454</fpage><lpage>459</lpage><pub-id pub-id-type="pmcid">PMC7368421</pub-id><pub-id pub-id-type="pmid">32693089</pub-id><pub-id pub-id-type="doi">10.1016/j.ijid.2020.07.016</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bello</surname><given-names>SO</given-names></name><etal/></person-group><article-title>Innovative, rapid, high throughput method for drug repurposing in a pandemic – a case study of SARS-CoV-2 and COVID-19</article-title><source>bioRxiv</source><year>2022</year><elocation-id>2022.12.25.521651</elocation-id><pub-id pub-id-type="doi">10.1101/2022.12.25.521651</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basile</surname><given-names>K</given-names></name><etal/></person-group><article-title>Cell-based Culture Informs Infectivity and Safe De-Isolation Assessments in Patients with Coronavirus Disease 2019</article-title><source>Clin Infect Dis</source><year>2021</year><volume>73</volume><fpage>E2952</fpage><lpage>E2959</lpage><pub-id pub-id-type="pmcid">PMC7665383</pub-id><pub-id pub-id-type="pmid">33098412</pub-id><pub-id pub-id-type="doi">10.1093/cid/ciaa1579</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahsavandi</surname><given-names>S</given-names></name><name><surname>Ebrahimi</surname><given-names>MM</given-names></name><name><surname>Sadeghi</surname><given-names>K</given-names></name><name><surname>Mosavi</surname><given-names>SZ</given-names></name><name><surname>Mohammadi</surname><given-names>A</given-names></name></person-group><article-title>Dose- and time-dependent apoptosis induced by avian H9N2 influenza virus in human cells</article-title><source>Biomed Res Int</source><year>2013</year><volume>2013</volume><elocation-id>524165</elocation-id><pub-id pub-id-type="pmcid">PMC3784084</pub-id><pub-id pub-id-type="pmid">24106708</pub-id><pub-id pub-id-type="doi">10.1155/2013/524165</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ates</surname><given-names>G</given-names></name><name><surname>Vanhaecke</surname><given-names>T</given-names></name><name><surname>Rogiers</surname><given-names>V</given-names></name><name><surname>Rodrigues</surname><given-names>RM</given-names></name></person-group><article-title>Assaying cellular viability using the neutral red uptake assay</article-title><source>Methods Mol Biol</source><year>2017</year><volume>1601</volume><fpage>19</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">28470514</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Repetto</surname><given-names>G</given-names></name><name><surname>del Peso</surname><given-names>A</given-names></name><name><surname>Zurita</surname><given-names>JL</given-names></name></person-group><article-title>Neutral red uptake assay for the estimation of cell viability/ cytotoxicity</article-title><source>Nat Protoc</source><year>2008</year><volume>3</volume><fpage>1125</fpage><lpage>1131</lpage><pub-id pub-id-type="pmid">18600217</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mowbray</surname><given-names>FI</given-names></name><name><surname>Fox-Wasylyshyn</surname><given-names>SM</given-names></name><name><surname>El-Masri</surname><given-names>MM</given-names></name></person-group><article-title>Univariate Outliers: A Conceptual Overview for the Nurse Researcher</article-title><source>Can J Nurs Res</source><year>2019</year><volume>51</volume><fpage>31</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">29969044</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group><article-title>A new method for identification of outliers in immunogenicity assay cut point data</article-title><source>J Immunol Methods</source><year>2020</year><volume>484-485</volume><elocation-id>112817</elocation-id><pub-id pub-id-type="pmid">32615125</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Severson</surname><given-names>WE</given-names></name><etal/></person-group><article-title>Development and validation of a high-throughput screen for inhibitors of SARS CoV and its application in screening of a 100,000-compound library</article-title><source>J Biomol Screen</source><year>2007</year><volume>12</volume><fpage>33</fpage><lpage>40</lpage><pub-id pub-id-type="pmcid">PMC9050465</pub-id><pub-id pub-id-type="pmid">17200104</pub-id><pub-id pub-id-type="doi">10.1177/1087057106296688</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sebaugh</surname><given-names>JL</given-names></name></person-group><article-title>Guidelines for accurate EC50/IC50 estimation</article-title><source>Pharm Stat</source><year>2011</year><volume>10</volume><fpage>128</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">22328315</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caly</surname><given-names>L</given-names></name><name><surname>Druce</surname><given-names>JD</given-names></name><name><surname>Catton</surname><given-names>MG</given-names></name><name><surname>Jans</surname><given-names>DA</given-names></name><name><surname>Wagstaff</surname><given-names>KM</given-names></name></person-group><article-title>The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro</article-title><source>Antiviral Res</source><year>2020</year><volume>178</volume><pub-id pub-id-type="pmcid">PMC7129059</pub-id><pub-id pub-id-type="pmid">32251768</pub-id><pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104787</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Momekov</surname><given-names>G</given-names></name><name><surname>Momekova</surname><given-names>D</given-names></name></person-group><article-title>Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens</article-title><source>Biotechnol Biotechnol Equip</source><year>2020</year><volume>34</volume><fpage>469</fpage><lpage>474</lpage></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmith</surname><given-names>VD</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Lohmer</surname><given-names>LRL</given-names></name></person-group><article-title>The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19</article-title><source>Clin Pharmacol Ther</source><year>2020</year><volume>108</volume><fpage>762</fpage><lpage>765</lpage><pub-id pub-id-type="pmcid">PMC7267287</pub-id><pub-id pub-id-type="pmid">32378737</pub-id><pub-id pub-id-type="doi">10.1002/cpt.1889</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smit</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Efficacy and Safety of High-Dose Ivermectin for Reducing Malaria Transmission (IVERMAL): Protocol for a Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Trial in Western Kenya</article-title><source>JMIR Res Protoc</source><year>2016</year><volume>5</volume><fpage>e213</fpage><pub-id pub-id-type="pmcid">PMC5133431</pub-id><pub-id pub-id-type="pmid">27856406</pub-id><pub-id pub-id-type="doi">10.2196/resprot.6617</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>TI</given-names></name><etal/></person-group><article-title>Antiviral Drug Discovery for the Treatment of COVID-19 Infections</article-title><source>Viruses</source><year>2022</year><volume>14</volume><pub-id pub-id-type="pmcid">PMC9143071</pub-id><pub-id pub-id-type="pmid">35632703</pub-id><pub-id pub-id-type="doi">10.3390/v14050961</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>KS</given-names></name><name><surname>Leeuwon</surname><given-names>SZ</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>WR</given-names></name></person-group><article-title>Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir</article-title><source>J Med Chem</source><year>2022</year><volume>65</volume><fpage>8686</fpage><lpage>8698</lpage><pub-id pub-id-type="pmcid">PMC9236210</pub-id><pub-id pub-id-type="pmid">35731933</pub-id><pub-id pub-id-type="doi">10.1021/acs.jmedchem.2c00404</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavan</surname><given-names>M</given-names></name><name><surname>Bolcato</surname><given-names>G</given-names></name><name><surname>Bassani</surname><given-names>D</given-names></name><name><surname>Sturlese</surname><given-names>M</given-names></name><name><surname>Moro</surname><given-names>S</given-names></name></person-group><article-title>Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332</article-title><source>J Enzyme Inhib Med Chem</source><year>2021</year><volume>36</volume><fpage>1646</fpage><lpage>1650</lpage><pub-id pub-id-type="pmcid">PMC8300928</pub-id><pub-id pub-id-type="pmid">34289752</pub-id><pub-id pub-id-type="doi">10.1080/14756366.2021.1954919</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>H</given-names></name><name><surname>El-Abassy</surname><given-names>OM</given-names></name><name><surname>Abdellatef</surname><given-names>HE</given-names></name><name><surname>Hendawy</surname><given-names>HAM</given-names></name><name><surname>El-Sayed</surname><given-names>HM</given-names></name></person-group><article-title>Simultaneous analysis of two drugs used as supportive treatment for COVID-19: comparative statistical studies and analytical ecological appraisal</article-title><source>BMC Chem</source><year>2022</year><volume>16</volume><fpage>72</fpage><pub-id pub-id-type="pmcid">PMC9514717</pub-id><pub-id pub-id-type="pmid">36167604</pub-id><pub-id pub-id-type="doi">10.1186/s13065-022-00860-8</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beigmohammadi</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Impact of vitamins A, B, C, D, and e supplementation on improvement and mortality rate in ICU patients with coronavirus-19: A structured summary of a study protocol for a randomized controlled trial</article-title><source>Trials</source><year>2020</year><volume>21</volume><fpage>614</fpage><pub-id pub-id-type="pmcid">PMC7336105</pub-id><pub-id pub-id-type="pmid">32631405</pub-id><pub-id pub-id-type="doi">10.1186/s13063-020-04547-0</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asad</surname><given-names>D</given-names></name><name><surname>Shuja</surname><given-names>SH</given-names></name></person-group><article-title>Role of folate, cobalamin, and probiotics in COVID-19 disease management [letter]</article-title><source>Drug Design Development and Therapy</source><year>2021</year><volume>15</volume><fpage>3709</fpage><lpage>3710</lpage><pub-id pub-id-type="pmcid">PMC8403566</pub-id><pub-id pub-id-type="pmid">34471347</pub-id><pub-id pub-id-type="doi">10.2147/DDDT.S333295</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abd El Hadi</surname><given-names>SR</given-names></name><name><surname>Zien El-Deen</surname><given-names>EE</given-names></name><name><surname>Bahaa</surname><given-names>MM</given-names></name><name><surname>Sadakah</surname><given-names>AA</given-names></name><name><surname>Yassin</surname><given-names>HA</given-names></name></person-group><article-title>COVID-19: Vaccine delivery system, drug repurposing and application of molecular modeling approach</article-title><source>Drug Des Devel Ther</source><year>2021</year><volume>15</volume><fpage>3313</fpage><lpage>3330</lpage><pub-id pub-id-type="pmcid">PMC8335551</pub-id><pub-id pub-id-type="pmid">34366663</pub-id><pub-id pub-id-type="doi">10.2147/DDDT.S320320</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lokhande</surname><given-names>KB</given-names></name><name><surname>Doiphode</surname><given-names>S</given-names></name><name><surname>Vyas</surname><given-names>R</given-names></name><name><surname>Swamy</surname><given-names>KV</given-names></name></person-group><article-title>Molecular docking and simulation studies on SARS-CoV-2 Mpro reveals Mitoxantrone, Leucovorin, Birinapant, and Dynasore as potent drugs against COVID-19</article-title><source>J Biomol Struct Dyn</source><year>2021</year><volume>39</volume><fpage>7294</fpage><lpage>7305</lpage><pub-id pub-id-type="pmcid">PMC7484567</pub-id><pub-id pub-id-type="pmid">32815481</pub-id><pub-id pub-id-type="doi">10.1080/07391102.2020.1805019</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y meng</given-names></name><etal/></person-group><article-title>Folic acid: a potential inhibitor against SARS-CoV-2 nucleocapsid protein</article-title><source>Pharm Biol</source><year>2022</year><volume>60</volume><fpage>862</fpage><lpage>878</lpage><pub-id pub-id-type="pmcid">PMC9132477</pub-id><pub-id pub-id-type="pmid">35594385</pub-id><pub-id pub-id-type="doi">10.1080/13880209.2022.2063341</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Folic acid restricts SARS-CoV-2 invasion by methylating ACE2</article-title><source>Front Microbiol</source><year>2022</year><volume>13</volume><elocation-id>980903</elocation-id><pub-id pub-id-type="pmcid">PMC9432853</pub-id><pub-id pub-id-type="pmid">36060767</pub-id><pub-id pub-id-type="doi">10.3389/fmicb.2022.980903</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Medina</surname><given-names>E</given-names></name><etal/></person-group><article-title>Effect of Ivermectin on Time to Resolution of Symptoms among Adults with Mild COVID-19: A Randomized Clinical Trial</article-title><source>JAMA - J Am Med Assoc</source><year>2021</year><volume>325</volume><fpage>1426</fpage><lpage>1435</lpage><pub-id pub-id-type="pmcid">PMC7934083</pub-id><pub-id pub-id-type="pmid">33662102</pub-id><pub-id pub-id-type="doi">10.1001/jama.2021.3071</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>SCL</given-names></name><etal/></person-group><article-title>Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities The I-TECH Randomized Clinical Trial</article-title><source>JAMA Intern Med</source><year>2022</year><volume>182</volume><fpage>426</fpage><lpage>435</lpage><pub-id pub-id-type="pmcid">PMC8980926</pub-id><pub-id pub-id-type="pmid">35179551</pub-id><pub-id pub-id-type="doi">10.1001/jamainternmed.2022.0189</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popp</surname><given-names>M</given-names></name><etal/></person-group><article-title>Ivermectin for preventing and treating COVID-19</article-title><source>Cochrane Database Syst Rev</source><year>2021</year><volume>2021</volume><elocation-id>CD015017</elocation-id><pub-id pub-id-type="pmcid">PMC8406455</pub-id><pub-id pub-id-type="pmid">34318930</pub-id><pub-id pub-id-type="doi">10.1002/14651858.CD015017.pub2</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buonfrate</surname><given-names>D</given-names></name><etal/></person-group><article-title>High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial</article-title><source>Int J Antimicrob Agents</source><year>2022</year><volume>59</volume><elocation-id>106516</elocation-id><pub-id pub-id-type="pmcid">PMC8734085</pub-id><pub-id pub-id-type="pmid">34999239</pub-id><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2021.106516</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaccour</surname><given-names>C</given-names></name><name><surname>Hammann</surname><given-names>F</given-names></name><name><surname>Ramon-Garcia</surname><given-names>S</given-names></name><name><surname>Rabinovich</surname><given-names>NR</given-names></name></person-group><article-title>Ivermectin and COVID-19: Keeping rigor in times of urgency</article-title><source>American Journal of Tropical Medicine and Hygiene</source><year>2020</year><volume>102</volume><fpage>1156</fpage><lpage>1157</lpage><pub-id pub-id-type="pmcid">PMC7253113</pub-id><pub-id pub-id-type="pmid">32314704</pub-id><pub-id pub-id-type="doi">10.4269/ajtmh.20-0271</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngan</surname><given-names>DK</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Xia</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>R</given-names></name></person-group><article-title>Repurposing drugs as COVID-19 therapies: A toxicity evaluation</article-title><source>Drug Discov Today</source><year>2022</year><volume>27</volume><fpage>1983</fpage><lpage>1993</lpage><pub-id pub-id-type="pmcid">PMC8983078</pub-id><pub-id pub-id-type="pmid">35395401</pub-id><pub-id pub-id-type="doi">10.1016/j.drudis.2022.04.001</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vandenberg</surname><given-names>LN</given-names></name><etal/></person-group><article-title>Hormones and endocrine-disrupting chemicals: Low-dose effects and nonmonotonic dose responses</article-title><source>Endocr Rev</source><year>2012</year><volume>33</volume><fpage>378</fpage><lpage>455</lpage><pub-id pub-id-type="pmcid">PMC3365860</pub-id><pub-id pub-id-type="pmid">22419778</pub-id><pub-id pub-id-type="doi">10.1210/er.2011-1050</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prichard</surname><given-names>L</given-names></name><name><surname>Barwick</surname><given-names>V</given-names></name></person-group><article-title>Preparation of Calibration Curves A Guide to Best Practice Contact Point: Prepared by</article-title><source>Lgc</source><year>2003</year><fpage>1</fpage><lpage>27</lpage></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nusholtz</surname><given-names>GS</given-names></name><name><surname>Hsu</surname><given-names>TP</given-names></name><name><surname>Luna</surname><given-names>MAG</given-names></name><name><surname>Didomenico</surname><given-names>L</given-names></name><name><surname>Kochekseraii</surname><given-names>SB</given-names></name></person-group><article-title>The Consequences of Average Curve Generation: Implications for Biomechanics Data</article-title><source>SAE Tech Pap</source><year>2010</year><fpage>1</fpage><lpage>18</lpage><comment>2010-Novem</comment><pub-id pub-id-type="pmid">21512901</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>F</given-names></name><name><surname>Maurer</surname><given-names>C</given-names></name><name><surname>Friedberg</surname><given-names>RC</given-names></name></person-group><article-title>International organization for standardization (ISO) 15189</article-title><source>Ann Lab Med</source><year>2017</year><volume>37</volume><fpage>365</fpage><lpage>370</lpage><pub-id pub-id-type="pmcid">PMC5500734</pub-id><pub-id pub-id-type="pmid">28643484</pub-id><pub-id pub-id-type="doi">10.3343/alm.2017.37.5.365</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janiaud</surname><given-names>P</given-names></name><name><surname>Serghiou</surname><given-names>S</given-names></name><name><surname>Ioannidis</surname><given-names>JPA</given-names></name></person-group><article-title>New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology</article-title><source>Cancer Treat Rev</source><year>2019</year><volume>73</volume><fpage>20</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">30572165</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chavda</surname><given-names>VP</given-names></name><etal/></person-group><article-title>A global picture: Therapeutic perspectives for COVID-19</article-title><source>Immunotherapy</source><year>2022</year><volume>14</volume><fpage>351</fpage><lpage>371</lpage><pub-id pub-id-type="pmcid">PMC8884157</pub-id><pub-id pub-id-type="pmid">35187954</pub-id><pub-id pub-id-type="doi">10.2217/imt-2021-0168</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name></person-group><article-title>COVID-19 Drug Development</article-title><source>J Microbiol Biotechnol</source><year>2022</year><volume>32</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="pmcid">PMC9628783</pub-id><pub-id pub-id-type="pmid">34866128</pub-id><pub-id pub-id-type="doi">10.4014/jmb.2110.10029</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shojaei</surname><given-names>A</given-names></name><name><surname>Salari</surname><given-names>P</given-names></name></person-group><article-title>COVID-19 and off label use of drugs: an ethical viewpoint</article-title><source>DARU J Pharm Sci</source><year>2020</year><volume>28</volume><fpage>789</fpage><lpage>793</lpage><pub-id pub-id-type="pmcid">PMC7207985</pub-id><pub-id pub-id-type="pmid">32385829</pub-id><pub-id pub-id-type="doi">10.1007/s40199-020-00351-y</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dasgupta</surname><given-names>N</given-names></name></person-group><article-title>Safety Consequences of Off-Label Drugs Used for COVID-19</article-title><source>Drug Safety</source><year>2021</year><volume>44</volume><fpage>399</fpage><lpage>402</lpage><pub-id pub-id-type="pmcid">PMC7934123</pub-id><pub-id pub-id-type="pmid">33666902</pub-id><pub-id pub-id-type="doi">10.1007/s40264-021-01056-0</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>Inhibition of SARS-CoV-2 induced CPE.</title><p>For Erythromycin, Retapamulin, Folic acid and Ivermectin high dose, medium dose and low dose respectively represent 10μM, 7.5μM and 5μM but for Pyridoxine the doses were 20 μM, 15 μM and 10 μM. The doses were selected based on achievable C<sub>max</sub> in human subjects at standard doses of the drugs. All concentrations of test drugs were found nontoxic to Vero cells. Analyses were performed with outliers because biological factors probably dictated differences<sup><xref ref-type="bibr" rid="R9">9</xref></sup>.</p></caption><graphic xlink:href="EMS159172-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Inhibition of SARS-CoV-2 Papain like protease</title><p>For Erythromycin, Retapamulin, Folic acid and Ivermectin, high dose, medium dose and low dose respectively represent 10μM, 5μM and 2.5μM but for Pyridoxine the doses were 20 μM, 10 μM and 5 μM. The doses were selected based on achievable C<sub>max</sub> in human subjects at standard doses of the drugs and to input dose doubling escalation method. All concentrations of test drugs were found nontoxic to Vero cells. Analyses were performed with outliers substituted by averaging or neighbourhood method because precision rather than biological factors probably dictated differences<sup><xref ref-type="bibr" rid="R9">9</xref></sup>.</p></caption><graphic xlink:href="EMS159172-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>Inhibition of SARS-CoV-2 Main protease (MPRO or 3CL protease)</title><p>For Erythromycin, Retapamulin, Folic acid and Ivermectin, high dose, medium dose and low dose respectively represent 10μM, 5μM and 2.5μM but for Pyridoxine the doses were 20 μM, 10 μM and 5 μM. The doses were selected based on achievable C<sub>max</sub> in human subjects at standard doses of the drugs and to input dose doubling escalation method. All concentrations of test drugs were found nontoxic to Vero cells. Analyses were performed with outliers substituted by averaging or neighbourhood method because precisions rather than biological factors probably dictated differences<sup><xref ref-type="bibr" rid="R9">9</xref></sup>.</p></caption><graphic xlink:href="EMS159172-f003"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><title>Inhibition of SARS-CoV-2 induced CPE in Vero Cells</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top">Drug</th><th align="left" valign="top">Maximal inhibition of CPE(%)</th><th align="left" valign="top">Dose at maximal observed<xref ref-type="table-fn" rid="TFN1">*</xref> inhibition of CPE(μM)</th><th align="left" valign="top">IC<sub>50</sub>(μM)</th><th align="left" valign="top">95% CI of IC<sub>50</sub> (μM)</th><th align="left" valign="top">P</th></tr></thead><tbody><tr><td align="left" valign="top">Erythromycin</td><td align="left" valign="top">76</td><td align="left" valign="top">10</td><td align="left" valign="top">3.27</td><td align="left" valign="top">2.68 to 3.93</td><td align="left" valign="top">&lt;0.05</td></tr><tr><td align="left" valign="top">Retapamulin</td><td align="left" valign="top">75</td><td align="left" valign="top">7.5</td><td align="left" valign="top">4.23</td><td align="left" valign="top">2.29 to 7.22</td><td align="left" valign="top">&lt;0.05</td></tr><tr><td align="left" valign="top">Pyridoxine</td><td align="left" valign="top">63</td><td align="left" valign="top">20</td><td align="left" valign="top">9.29</td><td align="left" valign="top">6.30 to 13.31</td><td align="left" valign="top">&lt;0.05</td></tr><tr><td align="left" valign="top">Folic Acid</td><td align="left" valign="top">42</td><td align="left" valign="top">5</td><td align="left" valign="top">3.19</td><td align="left" valign="top">2.16 to 4.49</td><td align="left" valign="top">&lt;0.05</td></tr><tr><td align="left" valign="top">Ivermectin</td><td align="left" valign="top">10</td><td align="left" valign="top">7.5</td><td align="left" valign="top">84.31</td><td align="left" valign="top">41.70 to 759.2</td><td align="left" valign="top">&gt;0.05</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>*</label><p id="P32">‘Maximal observed’ inhibition in this study is not the inherent maximum possible inhibition efficacy of the tested drug, but that observed within the dose range tested. These dose ranges were centred at achievable plasma concentration of the drugs at the current recommended doses except Ivermectin where ranges were derived from literature of concentrations previously found to inhibit SARS-CoV-2 proliferation<sup><xref ref-type="bibr" rid="R13">13</xref>–<xref ref-type="bibr" rid="R15">15</xref></sup>. Ivermectin cause non-significant inhibition of CPE and then at an IC<sub>50</sub> concentration not achievable in human plasma(800mcg/kg maximum single dose of ivermectin has C<sub>max</sub> 108.1ng/ml or 0.124 μM/ml)<sup><xref ref-type="bibr" rid="R16">16</xref></sup>. Analyses were performed with outliers because biological difference probably dictated differences<sup><xref ref-type="bibr" rid="R9">9</xref></sup></p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float" orientation="portrait"><label>Table 2</label><caption><title>Inhibition of SARS-CoV-2 Papain like protease(PP)</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top">Drug</th><th align="left" valign="top">Maximal inhibition of PP(%)</th><th align="left" valign="top">Dose at maximal observed<xref ref-type="table-fn" rid="TFN2">*</xref> inhibition of PP(μM)</th><th align="left" valign="top">IC<sub>50</sub>(μM)</th><th align="left" valign="top">95% CI of IC<sub>50</sub> (μM)</th><th align="left" valign="top">p</th></tr></thead><tbody><tr><td align="left" valign="top">Erythromycin</td><td align="left" valign="top">29.46</td><td align="left" valign="top">10.0</td><td align="left" valign="top">0.94</td><td align="left" valign="top">0.20 to 2.09</td><td align="left" valign="top">&lt;0.05</td></tr><tr><td align="left" valign="top">Retapamulin</td><td align="left" valign="top">20.60</td><td align="left" valign="top">5</td><td align="left" valign="top">0.88</td><td align="left" valign="top">0.45 to 1.42</td><td align="left" valign="top">&lt;0.05</td></tr><tr><td align="left" valign="top">Pyridoxine</td><td align="left" valign="top">17.46</td><td align="left" valign="top">20.0</td><td align="left" valign="top">1.14</td><td align="left" valign="top">0.30 to 2.23</td><td align="left" valign="top">&lt;0.05</td></tr><tr><td align="left" valign="top">Folic Acid</td><td align="left" valign="top">31.99</td><td align="left" valign="top">5</td><td align="left" valign="top">1.07</td><td align="left" valign="top">0.47 to 1.90</td><td align="left" valign="top">&lt;0.05</td></tr><tr><td align="left" valign="top">Ivermectin</td><td align="left" valign="top">34.34</td><td align="left" valign="top">10</td><td align="left" valign="top">1.51</td><td align="left" valign="top">0.55 to 3.07</td><td align="left" valign="top">&lt;0.05</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><label>*</label><p id="P33">‘Maximal observed’ inhibition in this study is not the inherent maximum possible inhibition efficacy of the tested drug, but that observed within the dose range tested. These dose ranges were centred at achievable plasma concentration of the drugs at the current recommended doses except Ivermectin where ranges were derived from literature of concentrations previously found to inhibit SARS-CoV-2 proliferation<sup><xref ref-type="bibr" rid="R13">13</xref>–<xref ref-type="bibr" rid="R15">15</xref></sup>. Ivermectin cause significant inhibition of PP but at an IC<sub>50</sub> concentration not achievable in human plasma(800mcg/kg maximum single dose of ivermectin has C<sub>max</sub> 108.1ng/ml or 0.124 μM/ml)<sup><xref ref-type="bibr" rid="R16">16</xref></sup>. Analyses were performed with substitution of outliers because precision rather than biological factors probably dictated differences<sup><xref ref-type="bibr" rid="R9">9</xref></sup>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float" orientation="portrait"><label>Table 3</label><caption><title>Inhibition of SARS-CoV-2 Main Protease(MPRO or 3CL)</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top">Drug</th><th align="left" valign="top">Maximal inhibition of M<sup>PRO</sup> (%)</th><th align="left" valign="top">Dose at maximal observed<xref ref-type="table-fn" rid="TFN3">*</xref> inhibition of M<sup>PRO</sup> (μM)</th><th align="left" valign="top">IC<sub>50</sub>(μM)</th><th align="left" valign="top">95% CI of IC<sub>50</sub> (μM)</th><th align="left" valign="top">P</th></tr></thead><tbody><tr><td align="left" valign="top">Erythromycin</td><td align="left" valign="top">30.51</td><td align="left" valign="top">2.5</td><td align="left" valign="top">1.35</td><td align="left" valign="top">0.90 to 1.91</td><td align="left" valign="top">&lt;0.05</td></tr><tr><td align="left" valign="top">Retapamulin</td><td align="left" valign="top">33.37</td><td align="left" valign="top">2.5</td><td align="left" valign="top">1.25</td><td align="left" valign="top">0.60 to 2.15</td><td align="left" valign="top">&lt;0.05</td></tr><tr><td align="left" valign="top">Pyridoxine</td><td align="left" valign="top">45.17</td><td align="left" valign="top">20.0</td><td align="left" valign="top">7.36</td><td align="left" valign="top">4.14 to 12.67</td><td align="left" valign="top">&lt;0.05</td></tr><tr><td align="left" valign="top">Folic Acid</td><td align="left" valign="top">26.8</td><td align="left" valign="top">2.5</td><td align="left" valign="top">1.15</td><td align="left" valign="top">0.81 to 1.56</td><td align="left" valign="top">&lt;0.05</td></tr><tr><td align="left" valign="top">Ivermectin</td><td align="left" valign="top">38.07</td><td align="left" valign="top">5.0</td><td align="left" valign="top">2.44</td><td align="left" valign="top">1.49 to 3.77</td><td align="left" valign="top">&lt;0.05</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><label>*</label><p id="P34">‘Maximal observed’ inhibition in this study is not the inherent maximum possible inhibition efficacy of the tested drug, but that observed within the dose range tested. These dose ranges were centred at achievable plasma concentration of the drugs at the current recommended doses except Ivermectin where ranges were derived from literature of concentrations previously found to inhibit SARS-CoV-2 proliferation<sup><xref ref-type="bibr" rid="R13">13</xref>–<xref ref-type="bibr" rid="R15">15</xref></sup>. Ivermectin cause significant inhibition of M<sup>PRO</sup> but at an IC<sub>50</sub> concentration not achievable in human plasma(800mcg/kg maximum single dose of ivermectin has C<sub>max</sub> 108.1ng/ml or 0.124 μM/ml)<sup><xref ref-type="bibr" rid="R16">16</xref></sup>. Analyses were performed with substitution of outliers because precision rather than biological factors probably dictated differences<sup><xref ref-type="bibr" rid="R9">9</xref></sup>.</p></fn></table-wrap-foot></table-wrap></floats-group></article>